{ 111件 }
Kamoshima H, Nomoto H, Yamashita K, Takahashi Y, Tsuchida K, Kuwabara S, Miya A, Cho KY, Kameda H, Nakamura A, Atsumi T, Taneda S, Kurihara Y, Aoki S, Ono Y, Miyoshi H.
Do the benefits of sodium-glucose cotransporter 2 inhibitors exceed the risks in patients with type 1 diabetes?
Endocrine Journal, in press.
IF: 2.349
Oba-Yamamoto C, Takeuchi J, Nakamura A, Nomoto H, Kameda H, Cho KY, Atsumi T, Miyoshi H Impact of low-starch high-fiber pasta on postprandial blood glucose.
Nutrition, Metabolism and Cardiovascular Diseases, in press.
IF: 4.222
Kawata S, Nakamura A, Miyoshi H, Yang K, Shigesawa I, Yamauchi Y, Tsuchida K, Omori K, Takahashi K, Nomoto H, Kameda H, Cho KY, Terauchi Y, Atsumi T.
Glucokinase activation leads to an unsustained hypoglycaemic effect with hepatic triglyceride accumulation in db/db mice.
Diebetes Obes Metab, in press.
IF: 6.57
Chiba K, Kameda H, Miya A, Nomoto H, Cho KY, Nakamura A, Jin S, Matoba K, Miyoshi H, Atsumi T.
False hypercortisolemia due to abnormal albumin-cortisol binding in a patient with familial dysalbuminemic hyperthyroxinemia.
Thyroid, in press.
IF: 6.568
Kameda R, Cho KY, Nomoto H, Nakamura A, Omori K, Nagai S, Edagawa S, Kawata S, Takeuchi J, Kameda H, Kurihara Y, Aoki S, Atsumi T, Miyoshi H, LUNA Study Investigators.
Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: a multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study) Diabetes Research and Clinical Practice, in press.
IF: 5.602
Nakamura A, Terauchi Y.
Impaired insulin secretion and related factors in East Asian individuals.
J Diabetes Investig, in press
IF: 3.761
Blencowe M, Furterer A, Wang Q, Gao F, Rosenberger M, Pei L, Nomoto H, Mawla AM, Huising MO, Coppola G, Yang X, Butler PC, Gurlo T.
IAPP induced beta cell stress recapitulates the islet transcriptome in type 2 diabetes Diabetologia, in press.
IF 10.122
Nakamura A, Omori K, Terauchi Y. Glucokinase activation or inactivation: Which will lead to the treatment of type 2 diabetes?
Diabetes Obes Metab, in press
IF: 5.900
Araki T, Tone Y, Yamamoto M, Kameda H, Ben-Shlomo A, Yamada S, Takeshita A, Yamamoto M, Kawakami Y, Tone M, Melmed S Two Distinctive POMC Promoters Modify Gene Expression in Cushing’s Disease J Clin Endocrinol Metab, in press.
IF: 5.399（英文・原著）
第4回若手臨床内分泌医奨励賞（Clinical Endocrinology KO Rounds） Runners-Up賞 野本 博司先生